Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Iterum Therapeutics (ITRM) stocks

Learn how to easily invest in Iterum Therapeutics stocks.

Iterum Therapeutics is a biotechnology business based in the US. Iterum Therapeutics stocks (ITRM.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $1.19 – an increase of 6.61% over the previous week. Iterum Therapeutics employs 14 staff and has a market cap (total outstanding stock value) of $14.7 million.

How to buy Iterum Therapeutics stock

  1. Choose a stock trading platform. Use our comparison table or choose from our Top Picks below.
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds unto your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – ITRM. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Promoted for Beginners

National Bank Direct Brokerage

  • Commission-free trading
  • Several account types available
  • Access to array of research tools

Promoted for Low Fees

CIBC Investor's Edge

  • Easy to use platform
  • Low fees
  • Student and young investor discounts

Best for Lowest Commissions

Finder Award

Interactive Brokers

  • Access to international stock exchanges
  • Low margin rates
  • Powerful research tools

Iterum Therapeutics stock price (NASDAQ:ITRM)

Use our graph to track the performance of ITRM stocks over time.

Iterum Therapeutics shares at a glance

Information last updated 2023-05-27.
Latest market close$1.21
52-week range$0.60 - $7.02
50-day moving average $1.08
200-day moving average $1.46
Wall St. target price$1.00
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-4.39

Buy Iterum Therapeutics stocks from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Note: The dollar amounts in the table below are in Canadian dollars.

1 - 5 of 5
Name Product Finder Rating Available Asset Types Stock Trading Fee Account Fee Signup Offer Table description
CIBC Investor's Edge
Finder Rating:
3.8 / 5
Stocks, Bonds, Options, Mutual Funds, ETFs
$0 if conditions met, or $100
An easy-to-use platform with access to a variety of tools to help you trade with confidence.
Interactive Brokers
Finder Rating:
4.3 / 5
Stocks, Bonds, Options, ETFs, Currencies, Futures
min $1.00, max 0.5%
Winner for Best Overall Broker in the Finder Stock Trading Platform Awards.
National Bank Direct Brokerage
Finder Rating:
4.2 / 5
Stocks, Bonds, Options, Mutual Funds, GICs
$0 if conditions met, or $100
Get $0 commission on all transactions with promo code: finder
Finder Rating:
4.3 / 5
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
$4.95 - $9.95
Get $50 in free trades when you fund your account with a minimum of $1,000.
Opt for self-directed investing and save on fees or get a pre-built portfolio to take out some of the guesswork.
Qtrade Direct Investing
Finder Rating:
3.7 / 5
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Get up to $150 sign-up bonus. Use promo code BONUS150. Conditions apply. Ends June 30, 2023.
Low trading commissions and an easy-to-use platform with access to powerful tools and a wide selection of investment options.

Is it a good time to buy Iterum Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Iterum Therapeutics price performance over time

Historical closes compared with the close of $1.21 from 2023-06-02

1 week (2023-05-26) 6.61%
1 month (2023-05-03) 7.08%
3 months (2023-03-03) -0.82%
6 months (2022-12-02) -12.95%
1 year (2022-06-03) 450.00%
2 years (2021-05-30) N/A
3 years (2020-06-03) 1.49
5 years (2018-06-01) 12.24
[/expander_content] [/expander]

Iterum Therapeutics financials

Gross profit TTM $37,000
Return on assets TTM -23.99%
Return on equity TTM -113.59%
Profit margin 0%
Book value $2.22
Market capitalisation $14.7 million

TTM: trailing 12 months

Iterum Therapeutics share dividends

We're not expecting Iterum Therapeutics to pay a dividend over the next 12 months.

Have Iterum Therapeutics's shares ever split?

Iterum Therapeutics's shares were split on a 1:15 basis on 18 August 2022. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Iterum Therapeutics shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Iterum Therapeutics shares which in turn could have impacted Iterum Therapeutics's share price.

Iterum Therapeutics share price volatility

Over the last 12 months, Iterum Therapeutics's shares have ranged in value from as little as $0.601 up to $7.017. A popular way to gauge a stock's volatility is its "beta".

ITRM.US volatility(beta: 1.61)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Iterum Therapeutics's is 1.6121. This would suggest that Iterum Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Iterum Therapeutics overview

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland. .

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site